Angiotensin Peptides Potentiate SARS-CoV-2 Spike–AXL Interaction: Mechanistic Insights and Research Implications

Study Background and Research Question

The renin-angiotensin system (RAS) plays a central role in cardiovascular physiology and pathology, notably in blood pressure regulation and fluid homeostasis. Its peptide hormones, such as angiotensin II and its truncated fragments, have well-established vasoconstrictor and dipsogenic effects. The emergence of SARS-CoV-2, the virus responsible for COVID-19, brought renewed attention to the intersection of RAS signaling and viral pathogenesis, as the viral spike protein primarily exploits the angiotensin-converting enzyme 2 (ACE2) receptor for cell entry. However, alternative receptors such as AXL have been implicated in facilitating infection, particularly in tissues with low ACE2 expression. The study by Oliveira et al. (2025) addresses the critical question: Do naturally occurring angiotensin peptides modulate the binding affinity of the SARS-CoV-2 spike protein for its key receptors, and if so, what are the implications for viral infectivity and disease progression?

Key Innovation from the Reference Study

The central innovation of the Oliveira et al. study lies in the discovery that truncated angiotensin peptides—especially shorter forms such as Angiotensin 1/2 (5-7), which has the amino acid sequence H2N-Ile-His-Pro-OH—substantially enhance the binding of the viral spike protein to the AXL receptor. While the canonical RAS focus has been on ACE2, this work demonstrates that the spectrum of biologically active angiotensin fragments can directly affect spike–receptor interactions beyond ACE2, revealing a previously unappreciated interface between cardiovascular peptide signaling and viral entry mechanisms.

Methods and Experimental Design Insights

Oliveira et al. utilized antibody-based binding assays to quantify the effects of various angiotensin fragments on SARS-CoV-2 spike protein binding to three relevant receptors: AXL, ACE2, and neuropilin-1 (NRP1). The team systematically tested the effects of full-length and truncated peptides derived from the classical RAS pathway, as well as chemically modified analogs. The experimental workflow included:

• Preparation of recombinant spike protein and receptor proteins (AXL, ACE2, NRP1).
• Incubation of spike protein with each peptide (including Angiotensin II, Angiotensin (1–7), Angiotensin (1–6), as well as N-terminally truncated forms such as Angiotensin IV and Angiotensin (5–7)).
• Quantification of spike–receptor binding via antibody-based detection and fluorescence measurement.
• Assessment of the effects of specific amino acid substitutions or post-translational modifications (e.g., tyrosine phosphorylation or substitution by valine).

This systematic approach allowed the researchers to map the structure–activity relationship of angiotensin fragments in enhancing spike–receptor interactions.

Core Findings and Why They Matter

The principal findings from the reference study are as follows:

• Angiotensin II (1–8) increases spike–AXL binding by two-fold, but not binding to ACE2 or NRP1.
• Shorter angiotensin peptides generated via C-terminal or N-terminal truncation, such as Angiotensin (1–7), Angiotensin (1–6), Angiotensin IV (3–8), and notably Angiotensin (5–7), exhibit even greater enhancing effects (up to 2.7-fold with Angiotensin IV).
• N-terminal truncation (e.g., Angiotensin (5–7), the H2N-Ile-His-Pro-OH peptide) results in peptides with the most potent spike–AXL binding enhancement.
• Chemical modifications at position 4 (tyrosine substitution/phosphorylation) further increase spike–AXL interaction, highlighting the importance of specific residue characteristics.
• Among the tested receptors, AXL is uniquely susceptible to this peptide-mediated enhancement, with only Angiotensin IV also modestly enhancing spike binding to ACE2 and NRP1.

These results are significant for both cardiovascular and infectious disease research. From a mechanistic perspective, they suggest that the RAS system—particularly its lesser-studied peptide fragments—can directly modulate viral entry by influencing spike–receptor interactions. This provides a molecular rationale for observed links between RAS dysregulation (e.g., in hypertension) and COVID-19 outcomes. Furthermore, the identification of Angiotensin 1/2 (5-7) as a potent modulator of spike–AXL binding opens new research avenues for targeting peptide–receptor dynamics in antiviral strategies.

Comparison with Existing Internal Articles

Several recent reviews and technical articles have highlighted the dual relevance of angiotensin peptides in cardiovascular and viral pathogenesis research. For example, Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding provides an in-depth analysis of the Oliveira et al. study, emphasizing how truncated forms like Angiotensin 1/2 (5-7) may act as bridges between RAS signaling and viral infection mechanisms. Similarly, Angiotensin 1/2 (5-7): Molecular Insights for Precision C... extends the discussion to molecular mechanisms and translational potential, integrating peptide–receptor interaction data with solubility optimization for experimental design. These internal resources corroborate the reference study’s findings and offer practical perspectives for integrating Angiotensin 1/2 (5-7) into both blood pressure regulation peptide workflows and SARS-CoV-2 research.

Limitations and Transferability

While the study by Oliveira et al. provides robust in vitro evidence for angiotensin peptide–mediated enhancement of spike–AXL binding, several limitations must be considered. First, the experimental system relies on recombinant proteins and may not fully recapitulate the complexity of in vivo peptide concentrations, local enzymatic processing, or receptor expression patterns. Additionally, the clinical relevance of these findings remains to be established—particularly whether circulating or tissue-specific levels of angiotensin fragments like Angiotensin 1/2 (5-7) are sufficient to influence viral infectivity in patients. The specificity of the effect for AXL (with only minor effects on ACE2 and NRP1) also suggests that tissue tropism and local peptide metabolism may be critical determinants. Finally, the study does not address downstream consequences of enhanced spike–AXL binding, such as effects on actual viral entry or replication, which remains an open area for future investigation.

Protocol Parameters

• Peptide concentration for binding assays: 1–10 μM range is recommended, as applied in antibody-based detection assays used in Oliveira et al. (2025).
• Recombinant protein preparation: Use high-purity spike protein and receptor ectodomains; ensure buffer compatibility for peptide solubility (e.g., Angiotensin 1/2 (5-7) is water-soluble at ≥50 mg/mL, according to the product information).
• Peptide modification studies: For examining residue-specific effects, introduce point mutations or post-translational modifications at position 4 (e.g., tyrosine to valine or tyrosine phosphorylation) to assess impact on spike–AXL binding.
• Short-term peptide solution storage: Prepare fresh working solutions immediately before use for maximal stability; longer-term storage as solid at -20°C is recommended.

Why this cross-domain matters, maturity, and limitations

The intersection of RAS peptide signaling and viral entry mechanisms—specifically the influence of angiotensin fragments on SARS-CoV-2 spike–AXL interactions—represents a novel cross-domain bridge. This relationship is important because it offers a mechanistic explanation for why patients with altered RAS activity (as in hypertension or cardiovascular disease) might experience different COVID-19 outcomes. Despite the compelling in vitro evidence, this cross-domain insight is still at an early stage of translational maturity. In vivo validation, assessment of physiological peptide concentrations, and exploration of therapeutic modulation are needed to determine the full impact and potential for clinical targeting.

Research Support Resources

Researchers interested in experimentally probing these spike–receptor dynamics or validating peptide–receptor interactions can employ synthetic peptides such as Angiotensin 1/2 (5-7) (SKU A1049), which is available at high purity and with reliable solubility profiles. The H2N-Ile-His-Pro-OH peptide is suitable for use in both biochemical binding assays and cell-based workflows relevant to renin-angiotensin system research, blood pressure regulation, and viral pathogenesis. For protocol optimization and troubleshooting, internal articles such as Angiotensin 1/2 (5-7): Streamlining Hypertension & Viral... and Applied Uses of Angiotensin 1/2 (5-7) in Hypertension Research provide detailed practical advice on integrating this peptide into diverse research programs.